Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Programs Update Interim Analysis for Phase 3 HONOR study of Tonmya (Cyclobenzaprine HCl Sublingual Tablets) in Military-Relat

Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial

Results and Provides Programs Update

Analysis for Phase 3 HONOR study of Tonmya (Cyclobenzaprine HCl Sublingual Tablets) in

Military-Related PTSD Expected in Third

Quarter of 2018; Topline Results Expected in Fourth Quarter of

YORK, March 12, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a clinical-stage biopharmaceutical

company focused on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and to improve

biodefense through developing potential medical counter-measures, today announced financial results for the fourth quarter and

full year ended December 31, 2017.

remain on track to report results from the interim analysis in the third quarter of this year for the Phase 3 HONOR study of Tonmya*,

an FDA-designated Breakthrough Therapy for the treatment of posttraumatic stress disorder (PTSD)," commented Seth Lederman,

M.D., President and Chief Executive Officer of Tonix. "The interim readout will be based on approximately 50 percent of

the total number of efficacy evaluable participants in the study and we anticipate reaching this 50 percent randomization level

in the first quarter of this year. Topline results of all efficacy evaluable participants, if needed, are anticipated in the fourth

addition," Dr. Lederman continued, "we are excited about developing a potential second indication for TNX-102 SL for

the treatment of agitation in Alzheimer's disease. We are on schedule to submit an Investigational New Drug (IND) application

to the FDA for a Phase 2 study in this indication before the end of this month."

December 31, 2017, Tonix had cash and cash equivalents of $25.5 million. Net cash used in operating activities for the full year

has been conditionally accepted by the U.S. Food and Drug Administration (FDA) as the proposed trade name for TNX-102 SL (cyclobenzaprine

HCl sublingual tablets) for PTSD. TNX-102 SL is an investigational new drug and has not been approved for any indication.

Quarter Financial Results

reported a net loss of $5.5 million, or $0.71 per share, for the fourth quarter of 2017, compared to a net loss of $7.5 million,

or $2.08 per share, for the fourth quarter of 2016. The net loss for the three months ended December 31, 2017, excluding non-cash

expenditures of $0.3 million, was $5.2 million, as compared to a net loss of $6.4 million, excluding non-cash expenditures of

$1.1 million, for the three months ended December 31, 2016. The reduced net loss was primarily due to decreased research and development

expenses for clinical studies and related research, as well as lower general and administrative expenses needed to support these

and other corporate development activities.

reported a net loss of $21.1 million, or $3.17 per share, for the year ended December 31, 2017, compared to a net loss of $38.8

million, or $15.41 per share, for the year ended December 31, 2016. The net loss for the year ended December 31, 2017, excluding

non-cash expenditures of $1.8 million, was $19.3 million, as compared to a net loss of $35.2 million, excluding non-cash expenditures

of $3.6 million, for the year ended December 31, 2016. The reduced net loss was primarily due to decreased research and development

expenses for clinical studies and related research, as well as lower general and administrative expenses needed to support these

and other corporate development activities.

used in operations was $19.1 million for the year ended December 31, 2017, as compared to $ 37.3 million for the year ended December

31, 2016. At December 31, 2017, Tonix's cash, cash equivalents and marketable securities totaled $25.5 million, compared

to $26.1 million at December 31, 2016.

Tonmya and the Phase 3 HONOR Study

is a patented sublingual transmucosal formulation of cyclobenzaprine that is in Phase 3 development. PTSD is a serious condition

characterized by chronic disability, inadequate treatment options, especially for military-related PTSD, and an overall high utilization

of healthcare services that contributes to significant economic burdens. In a Phase 2 study, Tonmya 5.6 mg (2 x 2.8 mg tablets),

was found to be effective in treating military-related PTSD, which formed the basis of the Breakthrough Therapy designation granted

by the FDA. Tonix is currently conducting a Phase 3 trial of Tonmya in military-related PTSD in the U.S., the HONOR study, which

is a 12-week randomized, double-blind, placebo-controlled trial evaluating the efficacy of Tonmya 5.6 mg in participants with

military-related PTSD. This two-arm, adaptive-design trial is targeting enrollment of up to approximately 550 participants in

approximately 40 U.S. sites. An unblinded interim analysis will be conducted once the study has accumulated efficacy results from

approximately 275 randomized participants. In a Cross-Disciplinary Breakthrough Therapy meeting, the FDA confirmed that (i) a

single-study NDA approval could be possible if the topline data from the HONOR study are statistically very persuasive, and (ii)

an additional abuse assessment study is not required for the NDA filing. Additional details of the HONOR study are available at

www.thehonorstudy.com or https://clinicaltrials.gov/ct2/show/NCT03062540.

2017, the U.S. Patent and Trademark Office issued a patent (U.S. Patent No. 9,636,408) protecting the composition and manufacture

of the unique Tonmya formulation. The Protectic protective eutectic and Angstro-Technology formulation are important

elements of Tonix's proprietary Tonmya composition. This patent is expected to provide Tonmya, upon NDA approval, with U.S.

market exclusivity until 2034. Tonix was also awarded European patent (Patent No. 2,501,234, "Methods and Compositions for

Treating Symptoms Associated with Posttraumatic Stress Disorders Using Cyclobenzaprine"). This patent is expected to provide

Tonmya, upon European marketing authorization, with European market exclusivity until November 2030 and the exclusivity may be

extended based on the timing of the European marketing authorization of Tonmya for PTSD. Also, in December 2017, the Japanese

Patent Office issued Japanese Patent No. 6259452, "Compositions and Methods for Transmucosal Absorption," related

to the pharmacokinetic profile of Tonmya, or TNX-102 SL.

Tonix Pharmaceuticals Holding Corp.

is a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat serious neuropsychiatric

conditions and to improve biodefense through developing potential medical counter-measures. Tonix's lead product candidate,

Tonmya, or TNX-102 SL, is in Phase 3 development as a bedtime treatment for PTSD. Tonix is also developing TNX-102 SL as a bedtime

treatment for agitation in Alzheimer's disease and has completed a pre-IND (Investigational New Drug) meeting with the FDA.

TNX-601 (tianeptine oxalate) is in the pre-IND application stage, also for the treatment of PTSD but designed for daytime dosing.

Tonix's lead biologic candidate, TNX-801, is a potential smallpox-preventing vaccine based on a live synthetic version of

horsepox virus, currently in the pre-IND application stage.

press release and further information about Tonix can be found at www.tonixpharma.com.

statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995.

These statements may be identified by the use of forward-looking words such as "anticipate," "believe,"

"forecast," "estimate," "expect," and "intend," among others. These forward-looking

statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors

that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include,

but are not limited to, risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations;

our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party

payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition.

As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization

of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read

the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2017, as filed with the Securities

and Exchange Commission (the "SEC") on March 9, 2018, and periodic reports filed with the SEC on or after the date

thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary

statements. The information set forth herein speaks only as of the date thereof.

PHARMACEUTICALS HOLDING CORP.

CONSOLIDATED STATEMENTS OF OPERATIONS

thousands, except share and per share amounts) (1)

PHARMACEUTICALS HOLDING CORP.

CONSOLIDATED BALANCE SHEETS